Login / Signup

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.

Roy FleischmannJeffrey R CurtisChristina Charles-SchoemanEduardo MyslerKunihiro YamaokaChristophe RichezHannah PalacDeanne DilleyJianzhong LiuSander StrengholtGerd-Rüdiger R Burmester
Published in: Annals of the rheumatic diseases (2023)
NCT02706873, NCT02675426, NCT02629159, NCT02706951, NCT02706847 and NCT03086343.
Keyphrases
  • phase iii
  • cardiovascular disease
  • rheumatoid arthritis
  • clinical trial
  • open label
  • type diabetes
  • study protocol
  • double blind
  • cardiovascular risk factors